Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Iterum Therapeutics (ITRM)

Iterum Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ITRM
DateTimeSourceHeadlineSymbolCompany
06/05/202413:00GlobeNewswire Inc.Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:ITRMIterum Therapeutics PLC
29/04/202413:00GlobeNewswire Inc.Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
28/03/202411:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ITRMIterum Therapeutics PLC
28/03/202411:00GlobeNewswire Inc.Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
21/03/202420:30GlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:ITRMIterum Therapeutics PLC
15/03/202412:00GlobeNewswire Inc.Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatNASDAQ:ITRMIterum Therapeutics PLC
06/03/202413:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
06/03/202413:00GlobeNewswire Inc.Iterum Therapeutics Provides Business UpdateNASDAQ:ITRMIterum Therapeutics PLC
30/01/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
30/01/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
30/01/202412:00PR Newswire (US)Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
29/12/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
14/12/202312:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
14/12/202312:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
04/12/202322:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
04/12/202322:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITRMIterum Therapeutics PLC
04/12/202313:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
04/12/202313:00GlobeNewswire Inc.Iterum Therapeutics Regains Compliance with Nasdaq Bid Price RuleNASDAQ:ITRMIterum Therapeutics PLC
07/11/202313:30GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:ITRMIterum Therapeutics PLC
24/10/202314:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
24/10/202313:00GlobeNewswire Inc.Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
12/10/202314:15GlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2023NASDAQ:ITRMIterum Therapeutics PLC
11/08/202312:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
11/08/202312:00GlobeNewswire Inc.Iterum Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
04/08/202322:00GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023NASDAQ:ITRMIterum Therapeutics PLC
01/08/202321:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
13/07/202312:07Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
06/07/202314:25Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
06/07/202314:24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
15/06/202322:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ITRMIterum Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ITRM